StimuSIL
Wilmington, US · Founded 2021 · Delaware corporation · 1 known investors
StimuSIL is a medical device company developing subdermal photobiomodulation technology that uses patented methods to deliver light-based stimulation beneath the skin's melanin layer for dermatology and aesthetics indications. Its lead preclinical candidate targets androgenetic alopecia (hair loss), with a research pipeline covering vitiligo, psoriasis, wrinkles, cellulite, and acne scars.
Founders & leadership
StimuSIL was founded in 2021 by Ana Isabel Villalba Villar.
AI
Ana Isabel Villalba VillarinFounder
AV
Ana Villalba VillarNamed on SEC filing
PV
Pablo VillalbaNamed on SEC filing
FY
Firat YerlikayaNamed on SEC filing
Board
AG
Abidin GulmusBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$2.3M disclosed across 4 rounds · 2022–2024
▶$600KraisedMar 2025 · 2 investors · BiotechnologyRule 506(b)
▶$600KraisedMar 2025 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Abidin GulmusDirector
- Ana Villalba VillarExecutive Officer, Director
- Pablo VillalbaExecutive Officer, Director
- Offering amount
- $600K
- Amount sold
- $600K
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.1MraisedMay 2024 · 7 investors · BiotechnologyRule 506(b)
▶$1.1MraisedMay 2024 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Firat YerlikayaDirector
- Pablo VillalbaExecutive Officer, Director
- Ana Villalba VillarExecutive Officer, Director
- Offering amount
- $1.1M
- Amount sold
- $1.1M
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$48.8KraisedSep 2023 · 1 investors · BiotechnologyRule 506(b)
▶$48.8KraisedSep 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Pablo VillalbaExecutive Officer, Director
- Firat YerlikayaDirector
- Ana Villalba VillarExecutive Officer, Director
- Offering amount
- $48.8K
- Amount sold
- $48.8K
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$575KraisedAug 2022 · 12 investors · BiotechnologyRule 506(b)
▶$575KraisedAug 2022 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Pablo VillalbaExecutive Officer, Director
- Ana Villalba VillarExecutive Officer, Director
- Firat YerlikayaDirector
- Offering amount
- $575K
- Amount sold
- $575K
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does StimuSIL do?
- StimuSIL is a medical device company developing subdermal photobiomodulation technology that uses patented methods to deliver light-based stimulation beneath the skin's melanin layer for dermatology and aesthetics indications. Its lead preclinical candidate targets androgenetic alopecia (hair loss), with a research pipeline covering vitiligo, psoriasis, wrinkles, cellulite, and acne scars.
- Who founded StimuSIL?
- StimuSIL was founded by Ana Isabel Villalba Villar in 2021.
- Who are StimuSIL's investors?
- StimuSIL's investors include Capital Cell.
- How much funding has StimuSIL raised?
- StimuSIL has disclosed $2.3M raised across 4 rounds.
- Where is StimuSIL headquartered?
- StimuSIL is headquartered in Wilmington, US.